跳至主要内容
临床试验/NCT04224025
NCT04224025招募中不适用

Influence of Breath- and Movementtherapy to Clinical and Molecular Parameter in Patients With Pulmonary Hypertension

Heidelberg University2 个研究点 分布在 1 个国家目标入组 250 人开始时间: 2015年11月3日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
250
试验地点
2
主要终点
6-minute Walking distance

研究概览

简要总结

The pulmonary hypertension is a disease, which tends to a progredient right heart failure. Although there was a large progress in development of medical therapy, the quality of life, the physical efficiency and the prognosis of the patients are still limited. The aim of the study is to examine the influence of physical training to clinical and molecular parameter.

详细描述

The aim of this prospective, randomized, controlled study in patients with pulmonary hypertension, who are under stable optimized treatment for at least 2 months, is to examine the effect of an additional exercise and respiratory therapy.

The aim criteria measures the clinical parameters to record the effect of the training plus molecular parameter to evaluate the effectiveness of the training. The molecular parameters are composed of laboratory parameter and inflammatory parameter as well as genetic analyses, measurements of epigenetic changes measured by microRNA Expressions and DNA-methylation.

The study parameters will be assessed in the patient's routine examinations. Clinical parameters comprise of hemodynamic assessment of pulmonary arterial pressure during exercise, pump function of left and right ventricle, and further echocardiographic parameters. Improvement of exercise capacity will be measured by the change of six-minute walking distance, the breathing economics, the world health organization functional class (WHO functional class), peak oxygen consumption and blood gas analysis. The quality of life will be assessed with the SF-36 questionnaire. Data for survival analysis will be gained by structured phone interviews . The safety of the training is warranted by long-term, rest- and stress-ECG, safety laboratory, systemic blood pressure, heart frequency, oxygen saturation and occurrence of adverse events.

Patients will be examined in the Thoraxklinik Heidelberg. Patients of the training group will take part in a specific, 3-week inpatient training program at the rehabilitation center Königstuhl Heidelberg. The training program consists of exercise and respiratory therapy as well as a mental gait training. Respiratory therapy will be performed 5 times/week for 30 minutes. Furthermore, 15-25 minutes low dosed interval training on a bicycle ergometer, dumbbell training of particular muscle groups with low weights and supervised walks on ground-level will be scheduled 5-7 times/week. Three- to five times a week a "mental gait training" is conducted to estimate the patient's individual physical abilities and limitations. The heart rate during exerciseand the intensity of the training will be closely monitored and individually adjusted. After three weeks of in-hospital rehabilitation the patients are asked to continue the training for twelve further weeks at home. All patients will be examined before the training program, at the end of the in-hospital phase after three weeks and after 15 weeks.

The control examinations cover the medical history, WHO functional class, physical examination, ECG, echocardiography at rest and during exercise, spiroergometry, quality of life, blood-gas analysis, lung function, 6-minute walking distance, oxygen saturation, blood pressure and heart rate, laboratory tests. An optional magnet resonance imaging at the beginning and after three months may also be conducted. At baseline, an optional genetic assessment will be performed; and at the beginning, after three and 15 weeks the expression levels of micro RNA and methylation of the DNA will be assessed. Medication will remain stable throughout the study.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Consent form
  • Men and women >18 years
  • Symptomatic PH (WHO-FC II-IV) invasive diagnostis with right heart catheterization: mPAP >25mmHg and a stable optimized treatment for at least 2 month
  • Patients who are able to understand and agree to participate in the study

排除标准

  • Pregnancy or breast feeding
  • Variation in the medication during the last 2 months
  • Patients with signs of right heart decompensation
  • Major walking problems
  • Unclear diagnosis
  • No invasive clarification of the PH
  • Acute illness, infections and fever
  • Grave lung disease with FEV1 <50% or TLC <70% from target
  • Further conclusion criteria are followed: acrive myokarditis, unstable angina pectoris, movement induced ventricular rhythmdisturbance, decompensation of the right hart insufficiency, meaningful heartvitien, hyperthrophic obstructive cardiomyopathie or a high grade reduced left ventricular pump function
  • Acute psychosis or other conditions which appears a reduced understanding
  • Patiets with metallic valvular or other metallic implants
  • Incorporated ferromagnetic materials or for the MRI incompatibel activce medicinal products
  • Claustrophobia

结局指标

主要结局

6-minute Walking distance

时间窗: change from baseline to final assessment after 3 months

Walking distance in metres

次要结局

  • Laboratory NT-proBNP(change from baseline to final assessment after 3 months)
  • Echocardiography right ventricular area(change from baseline to final assessment after 3 months)
  • Echocardiography right ventricular pump function(change from baseline to final assessment after 3 months)
  • Quality of life physical Summation score; scores from 0-100 with higher scores indicating better outcome(change from baseline to final assessment after 3 months)
  • Epigenetic mechanisms; changes in micro RNA methylation/expression(change from baseline to final assessment after 3 months)
  • Echocardiography tricuspid annular plane systolic excursion(change from baseline to final assessment after 3 months)
  • Quality of life mental Summation score; scores from 0-100 with higher scores indicating better outcome(change from baseline to final assessment after 3 months)
  • Workload during cardiopulmonary exercise testing(change from baseline to final assessment after 3 months)
  • Echocardiography right atrial area(change from baseline to final assessment after 3 months)
  • Peak oxygen consumption(change from baseline to final assessment after 3 months)
  • Ventilatory equivalent, assessed during cardiopulmonary exercise testing at Peak exercise(change from baseline to final assessment after 3 months)
  • Blood gas Analysis Oxygen saturation(change from baseline to final assessment after 3 months)
  • World Health Organization functional class(change from baseline to final assessment after 3 months)
  • Echocardiography systolic pulmonary arterial pressure(change from baseline to final assessment after 3 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Prof. Dr. med. Ekkehard Gruenig

Prof. Dr. med. Ekkehard Grünig, Head of centre for pulmonary hypertension

Thoraxklinik-Heidelberg gGmbH

研究点 (2)

Loading locations...

相似试验